Shoreline Biome Announces Name Change to Intus Biosciences

Share Article

New name, branding reflect company’s strategic transformation

News Image

Shoreline Biome, the developer of the industry-leading Titan-1TM microbiome research, discovery and testing platform, announced today that it has changed its name to Intus Biosciences.

Intus—a Latin word for “inside”— reflects the company’s focus on making advances in health and wellbeing by working inside the bacterial microbiome. The change marks Intus Biosciences’ strategic transformation from supplying research tools to providing complete data-driven solutions for microbiome discovery and understanding. The company’s unique and scalable Titan-1TM platform powers “sample to answer” services for pharmaceutical, diagnostic, and research partners, and supports cutting-edge testing for commercial laboratories to identify and track bacteria in unprecedented detail.

Intus Biosciences’ groundbreaking platform is a combination of patented assays and advanced proprietary analysis tools. Its ability to generate accurate, high-resolution (i.e., strain-level) data on a high-throughput basis is unprecedented. As the power of the technology has become known across the healthcare sector, partner and client demand for advanced services producing clear and actionable results, has driven the changes being announced today.

Shoreline Biome was founded by a team of scientists dedicated to making the microbiome as essential to healthcare as it is to our health. To overcome the issues that limit progress across the microbiome industry, they applied their deep expertise in next-generation sequencing to develop the technologies which today form the Titan-1TM platform.

“This is an incredibly exciting time for our company and the amazing team behind it,” said Paul Denslow, Intus Biosciences’ CEO. “An unmatched ability to produce actionable insights into the role of bacteria in the body and beyond, allows us to make extraordinary contributions across healthcare. Partners and clients have continually challenged us to deliver our highly differentiated technology in ever more creative and exciting ways. This has driven the shift to a data-centric platform model which our new name and dynamic branding reflect well.”

About Intus Biosciences, LLC
Intus Biosciences’ world-leading technology identifies bacteria and delivers answers about the microbiome with unprecedented detail, accuracy and scale. Its patented, validated Titan-1TM platform combines high-throughput assay and analysis technology and is unique in generating strain-level information. The company provides research and commercial services across global pharmaceutical, diagnostic, and testing industries; is active in health, agricultural, and environmental fields; and continues to develop innovative new partnerships, technologies, and applications.

To learn more or to partner with Intus Biosciences, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dawn Gratalo
Visit website